Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough

被引:44
作者
Hammer, J [1 ]
Schmidt, B [1 ]
机构
[1] Univ Vienna, Innere Med Klin 4, Gastroenterol & Hepatol Abt, A-1090 Vienna, Austria
关键词
D O I
10.1111/j.1365-2036.2004.01949.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Twice-daily dosing is increasingly used to improve gastric acid control, although not all proton-pump inhibitors are more effective when doses are split. Standard dose esomeprazole provides better gastric acid control than other standard dose proton-pump inhibitors. Aims: To compare the effect of standard dose esomeprazole (1 x 40 mg) with 20 mg b.d. on gastric acidity. Methods: Thirteen healthy subjects participated in this crossover study, receiving esomeprazole 2 x 20 mg and 1 x 40 mg for 7 days in random order with a washout period of at least 7 days. Gastric 24-h pH was measured on days 1, 2 and 6. Results: Median gastric 24-h pH was higher during 2 x 20 mg esomeprazole on day 2 (P < 0.01), no differences were detected on day 6. Night-time gastric acid suppression was significantly improved by 2 x 20 mg esomeprazole on all study days (P < 0.05). Nocturnal acid breakthrough was observed on all study days in subjects receiving 1 x 40 mg, but in only 85% (first night), 64% (second night), and 45% of subjects (sixth night) with 2 x 20 mg (P < 0.05). Conclusion: Splitting the esomeprazole dose improves initial acid suppression, this effect starts at the first night. Maximal benefit is achieved on day 2, while the effect on night-time acid control is detectable during the entire first week of treatment.
引用
收藏
页码:1105 / 1110
页数:6
相关论文
共 29 条
[1]   Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole [J].
Andersson, T ;
Hassan-Alin, M ;
Hasselgren, G ;
Röhss, K ;
Weidolf, L .
CLINICAL PHARMACOKINETICS, 2001, 40 (06) :411-426
[2]   Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects [J].
Armstrong, D ;
Bair, D ;
James, C ;
Tanser, L ;
Escobedo, S ;
Nevin, K .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (07) :705-711
[3]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[4]  
Castell DO, 2002, AM J GASTROENTEROL, V97, P575
[5]   Review article: pharmacology of esomeprazole and comparisons with omeprazole [J].
Dent, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 :5-9
[6]   Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough [J].
Fackler, WK ;
Ours, TM ;
Vaezi, MF ;
Richter, JE .
GASTROENTEROLOGY, 2002, 122 (03) :625-632
[7]   Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole [J].
Gillen, D ;
Wirz, AA ;
Neithercut, WD ;
Ardill, JES ;
McColl, KEL .
GUT, 1999, 44 (04) :468-475
[8]   Medical therapy - Management of the refractory patient [J].
Hatlebakk, JG ;
Katz, PO ;
Castell, DO .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (04) :847-+
[9]   Review article: gastric acidity - comparison of esomeprazole with other proton pump inhibitors [J].
Hatlebakk, JG .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 :10-15
[10]  
Hatlebakk JG, 1998, ALIMENT PHARM THERAP, V12, P1235